Related Experiment Video
Updated: Jun 8, 2025
New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
Published on: May 30, 2013
Penta Network: State-of-the-Art Research in Pediatric Human Immunodeficiency Virus
Pablo Rojo1, Cinta Moraleda2, Carlo Giaquinto3
1Department of Pediatrics, Pediatric Infectious Diseases Unit, Universidad Complutense, Avenida Puerta de Hierro, Madrid 28040, Spain.
Insights
The Penta Network advances pediatric HIV treatment and remission strategies through global clinical trials. Their work improves antiretroviral drugs and addresses critical issues like severe pneumonia in children.
Area of Science:
- Pediatric infectious diseases
- Clinical pharmacology
- Immunology
Background:
- The Penta Network has significantly contributed to pediatric human immunodeficiency virus (HIV) research.
- Initial focus was on European clinical trials, expanding globally to high-prevalence regions.
Purpose of the Study:
- To establish superior HIV treatments for children.
- To develop strategies for HIV remission in children.
- To address advanced HIV disease and improve antiretroviral formulations for pediatric use.
Main Methods:
- Conducted the ODYSSEY trial establishing dolutegravir efficacy.
- Initiated the 'Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies' (EPICC) consortium.
- Launched empirical and thrive projects focusing on advanced HIV disease.
Main Results:
- Dolutegravir identified as a superior treatment for pediatric HIV.
- Development of novel immunotherapeutic strategies for HIV remission is underway.
- Research addresses severe pneumonia and postdischarge mortality in children with advanced HIV.
Conclusions:
- The Penta Network is crucial in advancing pediatric HIV care globally.
- Collaborative efforts are essential for developing better pediatric antiretroviral drugs.
- Ongoing research targets HIV remission and improved outcomes for children living with HIV.
Abstract:
The Penta Network has made significant strides in pediatric human immunodeficiency virus (HIV) research, initially focusing on clinical trials for children in Europe, before expanding globally to countries with high HIV prevalence. Key contributions include the ODYSSEY trial, which established dolutegravir as a superior treatment for children and the Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies consortium, aimed at developing strategies for HIV remission. The ongoing empirical and thrive projects address advanced HIV disease, particularly severe pneumonia and postdischarge mortality in children. Going beyond clinical trials, the Penta Network also plays a key role in bringing stakeholders and industry together to achieve better antiretroviral formulations for children.
